Hemodialysis-Resistant Hypertension: Control with an Orally Active Inhibitor of Angiotensin-Converting Enzyme*
Key result
Captopril dramatically lowered blood pressure before and during dialysis in two patients with end-stage renal disease and dialysis-resistant hypertension.
Why the study?
Does captopril reduce blood pressure in patients with end stage renal disease and dialysis-resistant hypertension?
Population
2 patients with end stage renal disease and dialysis-resistant hypertension
Design
Case_series
Authors
Discussion
Loading...
Member takes
Implication
May support captopril trial before nephrectomy in ESRD; case report leaves open need for controlled confirmation.
Structured PICO
Does captopril reduce blood pressure in patients with end stage renal disease and dialysis-resistant hypertension?
P
Population
2 patients with end stage renal disease and dialysis-resistant hypertension
I
Intervention
Captopril (orally active inhibitor of angiotensin-converting enzyme)
O
Outcome
Blood pressure reduction before and during dialysissurrogate
Captopril may serve as an effective alternative to bilateral nephrectomy for controlling dialysis-resistant hypertension in ESRD patients.
Cite This Study
Vaughan et al. (1979) studied this question. Captopril dramatically lowered blood pressure before and during dialysis in two patients with end-stage renal disease and dialysis-resistant hypertension.